Hepatitis delta virus infection in Turkey : A meta-analysis of prevalence
© 2024 The Author(s)..
Objectives: Hepatitis delta virus (HDV) infection has been granted orphan disease status by the US Food and Drug Administration and the European Medicines Agency owing to its rarity and relatively limited research and treatment options. Turkey is considered an endemic country for the virus. We aimed to provide a current and updated country- and region-specific HDV infection prevalence.
Methods: In this meta-analysis, we searched databases, including MEDLINE, PUBMED, EMBASE, and UlakBim (Turkish Medical Index) published between January 1, 2006, and December 31, 2022. We included blood donor studies, outpatient clinic studies that comprised patients without cirrhosis, and inpatient clinical studies that comprised patients with cirrhosis. Turkey was divided into three regions: West, Central, and East Turkey.
Results: After a systematic assessment, 41 studies were included. Using a random-effects model, the estimated HDV prevalence among hepatitis B surface antigen-positive blood donors, outpatient clinic, and inpatient clinic patients were 3.37% (confidence interval [CI] 1.99-6.11), 5.05% (CI 4.00-6.23), and 29.06% (CI 10.45-51.79), respectively. The HDV prevalence among outpatient clinic patients in Western, Central, and Eastern regions were 3.38% (CI 2.47-4.44), 2.15% (CI 1.37-3.09), and 9.81% (CI 6.61-13.55), respectively.
Conclusions: East Turkey continues to have a high burden of HDV. Public health efforts, such as screening, should be targeted accordingly.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
IJID regions - 10(2024) vom: 30. März, Seite 228-234 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Toy, Mehlika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Delta hepatitis |
|---|
| Anmerkungen: |
Date Revised 07.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ijregi.2024.02.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369343913 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369343913 | ||
| 003 | DE-627 | ||
| 005 | 20240307232705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijregi.2024.02.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM369343913 | ||
| 035 | |a (NLM)38444561 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Toy, Mehlika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis delta virus infection in Turkey |b A meta-analysis of prevalence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Objectives: Hepatitis delta virus (HDV) infection has been granted orphan disease status by the US Food and Drug Administration and the European Medicines Agency owing to its rarity and relatively limited research and treatment options. Turkey is considered an endemic country for the virus. We aimed to provide a current and updated country- and region-specific HDV infection prevalence | ||
| 520 | |a Methods: In this meta-analysis, we searched databases, including MEDLINE, PUBMED, EMBASE, and UlakBim (Turkish Medical Index) published between January 1, 2006, and December 31, 2022. We included blood donor studies, outpatient clinic studies that comprised patients without cirrhosis, and inpatient clinical studies that comprised patients with cirrhosis. Turkey was divided into three regions: West, Central, and East Turkey | ||
| 520 | |a Results: After a systematic assessment, 41 studies were included. Using a random-effects model, the estimated HDV prevalence among hepatitis B surface antigen-positive blood donors, outpatient clinic, and inpatient clinic patients were 3.37% (confidence interval [CI] 1.99-6.11), 5.05% (CI 4.00-6.23), and 29.06% (CI 10.45-51.79), respectively. The HDV prevalence among outpatient clinic patients in Western, Central, and Eastern regions were 3.38% (CI 2.47-4.44), 2.15% (CI 1.37-3.09), and 9.81% (CI 6.61-13.55), respectively | ||
| 520 | |a Conclusions: East Turkey continues to have a high burden of HDV. Public health efforts, such as screening, should be targeted accordingly | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Delta hepatitis | |
| 650 | 4 | |a Meta-analysis of prevalence | |
| 650 | 4 | |a Orphan disease | |
| 650 | 4 | |a Turkey | |
| 700 | 1 | |a Güler, Begüm |e verfasserin |4 aut | |
| 700 | 1 | |a Somay, Kayra |e verfasserin |4 aut | |
| 700 | 1 | |a Gençdal, Genco |e verfasserin |4 aut | |
| 700 | 1 | |a Yurdaydin, Cihan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t IJID regions |d 2021 |g 10(2024) vom: 30. März, Seite 228-234 |w (DE-627)NLM342413988 |x 2772-7076 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g day:30 |g month:03 |g pages:228-234 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijregi.2024.02.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |b 30 |c 03 |h 228-234 | ||